July 17, 2014 8:33 AM | 1 min read |
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
In a report published Thursday, Bank of America analyst Steve Byrne reiterated a Buy rating on
Pacira Pharmaceuticals (NASDAQ: PCRX), and raised the price target from $86.00 to $104.00.In the report, Bank of America noted, “We are raising our PO to $104 (from $86) based on positive results from our Exparel survey, including a meaningful change in the outlook from anesthesiologists and expectations for significant revenue growth. We see upside from use in the nerve block indication (March 5, 2015 PDUFA date) as anesthesiologists in our survey stated they would use Exparel in roughly half of their nerve block procedures if approved."We modestly adjusted our peak market share in nerve block to 25% (from 20%) and increased our 2021 peak sales to $2.3bn (from $2.1bn), which assumes some IP extension potential (spray based technology would extend IP to 2031) and expansion of PCRX' manufacturing capacity (readily replicable in our view). We see upside from other DepoFoam–derived products such as NSAIDs.”Pacira Pharmaceuticals closed on Wednesday at $85.14.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.